cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.18610166
title: Public Perceptions of Anti-Corruption Efforts in Ukraine: 2023-2025 – Merged data from nationwide public opinion surveys conducted by the Kyiv International Institute of Sociology

description: The dataset includes data from three waves of nationwide surveys conducted by the Kyiv International Institute of Sociology (KIIS) among Ukraine's adult population in 2023, 2024, and 2025 on a question related to public perceptions of anti-corruption efforts.
Respondents were asked:
Information about corruption investigations, arrests, and detentions regularly appears in the media. For you personally, does this rather indicate that…
1.	There are indeed attempts to fight corruption in Ukraine, and there are positive developments
2.	Ukraine is hopelessly corrupt, and there are no positive changes
The merged dataset combines data from the three survey waves, each with a sample of approximately 1,000 respondents.
All survey waves were conducted using the computer-assisted telephone interview (CATI) method with adult (18 years and older) citizens of Ukraine residing in government-controlled territory.
The background information includes respondents' demographics (gender, age, education, nationality, occupation, self-assessment of financial situation, language) and residence information (oblast and type of settlement).
The combined dataset allows for analyzing trends in public perceptions over time, as well as the relationship between perceptions of anti-corruption efforts and respondents' demographic characteristics.
The data are available in SAV format (Ukrainian and English) and as a converted CSV file accompanied by a codebook.
The Data Documentation includes a short overview and discussion of survey results (with frequency tables in Annex 1).
description: Published on Discuss Data, https://discuss-data.net/dataset/7909ee70-a8cd-4085-98c8-fa63e0170c86/
Dataset creation: 2023-2025
description: Method(s) of data collection: Public Opinion Poll
DOI: 10.5281/zenodo.18610165
title: Public Perceptions of Anti-Corruption Efforts in Ukraine: 2023-2025 – Merged data from nationwide public opinion surveys conducted by the Kyiv International Institute of Sociology

description: The dataset includes data from three waves of nationwide surveys conducted by the Kyiv International Institute of Sociology (KIIS) among Ukraine's adult population in 2023, 2024, and 2025 on a question related to public perceptions of anti-corruption efforts.
Respondents were asked:
Information about corruption investigations, arrests, and detentions regularly appears in the media. For you personally, does this rather indicate that…
1.	There are indeed attempts to fight corruption in Ukraine, and there are positive developments
2.	Ukraine is hopelessly corrupt, and there are no positive changes
The merged dataset combines data from the three survey waves, each with a sample of approximately 1,000 respondents.
All survey waves were conducted using the computer-assisted telephone interview (CATI) method with adult (18 years and older) citizens of Ukraine residing in government-controlled territory.
The background information includes respondents' demographics (gender, age, education, nationality, occupation, self-assessment of financial situation, language) and residence information (oblast and type of settlement).
The combined dataset allows for analyzing trends in public perceptions over time, as well as the relationship between perceptions of anti-corruption efforts and respondents' demographic characteristics.
The data are available in SAV format (Ukrainian and English) and as a converted CSV file accompanied by a codebook.
The Data Documentation includes a short overview and discussion of survey results (with frequency tables in Annex 1).
description: Published on Discuss Data, https://discuss-data.net/dataset/7909ee70-a8cd-4085-98c8-fa63e0170c86/
Dataset creation: 2023-2025
description: Method(s) of data collection: Public Opinion Poll
DOI: 10.15468/dl.82kkuy
title: Occurrence Download

description: A dataset listing the 609 species recorded in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((4.99292 45.66402,4.98099 45.65476,5.00485 45.64271,5.038 45.63436,5.06651 45.63668,5.09767 45.65846,5.11557 45.7071,5.10391 45.81528,5.08281 45.83714,5.07355 45.84466,5.07492 45.84966,5.09028 45.85465,5.06843 45.85798,5.05819 45.84276,5.07833 45.82302,5.09024 45.74368,5.08534 45.68291,5.0743 45.66064,5.04489 45.65207,4.99292 45.66402))",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "PublishingOrg is 1928bdf0-f5d2-11dc-8c12-b8a03c50a862",
 "Year 2016-2026"
 ]
}

 The dataset's 609 records were derived from 41 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008542-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ekhrng
title: Occurrence Download

description: A dataset containing 1320 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mallotus barbatus",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is Fossil"
 ]
 }
 }
 ]
}

 The dataset includes 1320 records from 35 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008560-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xjwjv6
title: Occurrence Download

description: A dataset containing 16 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Tritonia marlothii",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 16 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008559-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.zeds5s
title: Occurrence Download

description: A dataset containing 568142 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Europe",
 "Country is Sweden",
 "GadmGid is SWE.12.5_1",
 "Geometry POLYGON((15.38823 58.28987,15.75435 58.28987,15.75435 58.49528,15.38823 58.49528,15.38823 58.28987))",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "Year 2020-2026"
 ]
}

 The dataset includes 568142 records from 24 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008478-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.23905063
title: Safety of BCG vaccination and revaccination in healthcare workers

description: BCG vaccination and revaccination are increasingly being considered for the protection of adolescents and adults against tuberculosis and, more broadly, for the off-target protective immunological effects against other infectious and noninfectious diseases. Within an international randomized controlled trial of BCG vaccination in healthcare workers (the BRACE trial), we evaluated the incidence of local and serious adverse events, as well as the impact of previous BCG vaccination on local injection site reactions (BCG revaccination). Prospectively collected data from 99% (5351/5393) of participants in Australia, Brazil, Spain, The Netherlands and the UK was available for analysis. Most BCG recipients experienced the expected self-limiting local injection site reactions (pain, tenderness, erythema, swelling). BCG injection site itch was an additional common initial local symptom reported in 49% of BCG recipients. Compared to BCG vaccination in BCG-naïve individuals, BCG revaccination was associated with increased frequency of mild injection site reactions, as well as earlier onset and shorter duration of erythema and swelling, which were generally self-limiting. Injection site abscess and regional lymphadenopathy were the most common adverse events and had a benign course. Self-resolution occurred within a month in 80% of abscess cases and 100% of lymphadenopathy cases. At a time when BCG is being increasingly considered for its off-target effects, our findings indicate that BCG vaccination and revaccination have an acceptable safety profile in adults.
DOI: 10.6084/m9.figshare.23905063.v1
title: Safety of BCG vaccination and revaccination in healthcare workers

description: BCG vaccination and revaccination are increasingly being considered for the protection of adolescents and adults against tuberculosis and, more broadly, for the off-target protective immunological effects against other infectious and noninfectious diseases. Within an international randomized controlled trial of BCG vaccination in healthcare workers (the BRACE trial), we evaluated the incidence of local and serious adverse events, as well as the impact of previous BCG vaccination on local injection site reactions (BCG revaccination). Prospectively collected data from 99% (5351/5393) of participants in Australia, Brazil, Spain, The Netherlands and the UK was available for analysis. Most BCG recipients experienced the expected self-limiting local injection site reactions (pain, tenderness, erythema, swelling). BCG injection site itch was an additional common initial local symptom reported in 49% of BCG recipients. Compared to BCG vaccination in BCG-naïve individuals, BCG revaccination was associated with increased frequency of mild injection site reactions, as well as earlier onset and shorter duration of erythema and swelling, which were generally self-limiting. Injection site abscess and regional lymphadenopathy were the most common adverse events and had a benign course. Self-resolution occurred within a month in 80% of abscess cases and 100% of lymphadenopathy cases. At a time when BCG is being increasingly considered for its off-target effects, our findings indicate that BCG vaccination and revaccination have an acceptable safety profile in adults.
DOI: 10.6084/m9.figshare.23819134
title: Parental intention to vaccinate children against seasonal influenza in the Eastern Mediterranean region: A cross-sectional study using the health belief model

description: Seasonal influenza vaccine is the most effective strategy for reducing influenza incidence and severity. Parental decision-making regarding childhood vaccination is influenced by one’s vaccine-related beliefs. A cross-sectional study was conducted to determine the role of the Health Belief Model (HBM) in predicting parental intention to vaccinate their children against influenza in the Eastern Mediterranean Region (EMR). An anonymous online survey was distributed to parents of children aged 6 months to 18 years in 14 EMR countries. Out of the 5964 participants, 28.2% intended to vaccinate their children against influenza. Urban residents (OR = 0.55, 95%CI: 0.35–0.85), decision-making regarding child’s health by the father alone (OR = 0.43, 95%CI: 0.34–0.55) or the mother alone (OR = 0.78, 95%CI: 0.65–0.93), having a child with a chronic illness (OR = 0.45, 95%CI: 0.38–0.53), reporting high perceived severity, susceptibility, and benefits (OR = 0.35, 95%CI: 0.30–0.40), and cues to action (OR = 0.45, 95%CI: 0.39–0.51) were inversely associated with parental unwillingness to vaccinate their children against influenza. While parents with a higher number of children in the household (OR = 1.08, 95%CI:1.03–1.12) and higher perceived barriers (OR = 2.92, 95%CI: 2.56–3.34) showed an increased likelihood of unwillingness to vaccinate their children. Interventions targeting parental beliefs and perceptions are necessary to improve influenza vaccination acceptance and coverage among children.
DOI: 10.6084/m9.figshare.23819134.v1
title: Parental intention to vaccinate children against seasonal influenza in the Eastern Mediterranean region: A cross-sectional study using the health belief model

description: Seasonal influenza vaccine is the most effective strategy for reducing influenza incidence and severity. Parental decision-making regarding childhood vaccination is influenced by one’s vaccine-related beliefs. A cross-sectional study was conducted to determine the role of the Health Belief Model (HBM) in predicting parental intention to vaccinate their children against influenza in the Eastern Mediterranean Region (EMR). An anonymous online survey was distributed to parents of children aged 6 months to 18 years in 14 EMR countries. Out of the 5964 participants, 28.2% intended to vaccinate their children against influenza. Urban residents (OR = 0.55, 95%CI: 0.35–0.85), decision-making regarding child’s health by the father alone (OR = 0.43, 95%CI: 0.34–0.55) or the mother alone (OR = 0.78, 95%CI: 0.65–0.93), having a child with a chronic illness (OR = 0.45, 95%CI: 0.38–0.53), reporting high perceived severity, susceptibility, and benefits (OR = 0.35, 95%CI: 0.30–0.40), and cues to action (OR = 0.45, 95%CI: 0.39–0.51) were inversely associated with parental unwillingness to vaccinate their children against influenza. While parents with a higher number of children in the household (OR = 1.08, 95%CI:1.03–1.12) and higher perceived barriers (OR = 2.92, 95%CI: 2.56–3.34) showed an increased likelihood of unwillingness to vaccinate their children. Interventions targeting parental beliefs and perceptions are necessary to improve influenza vaccination acceptance and coverage among children.
DOI: 10.6084/m9.figshare.24323094
title: Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine

description: The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses a challenge to determine the optimal updated composition of the coronavirus disease 2019 (COVID-19) vaccine. The present study aimed to investigate the immunogenicity of the Delta monovalent vaccine, the Omicron monovalent vaccine, and the Delta and Omicron BA.1 bivalent vaccine. Three COVID-19 vaccines were designed using the heterologous DNA prime-protein boost strategy, with each vaccine containing either Delta receptor-binding domain (RBD) of the spike protein, Omicron RBD, or both Delta and Omicron antigens. Temporal serum antibody binding titers and neutralizing antibody titers induced by the three vaccines in New Zealand White rabbits were analyzed. To further dissect the vaccine elicited antibodies (mAb) responses at the molecular level, a panel of rabbit monoclonal antibodies (RmAbs) was generated by a high-throughput single B cell sorting and discovery pipeline and further comprehensively characterized. The Omicron monovalent vaccine induced higher antibody binding titers and neutralization activities than the Delta and Omicron bivalent vaccine. Four RmAbs with robust neutralization capacity were isolated from rabbits immunized with the Omicron or Delta monovalent vaccine. Notably, 9E11 isolated from the Omicron monovalent vaccine group neutralized all the Omicron subvariants with an IC<sub>50</sub> value ranging from 1.5 to 503.6 ng/mL; thus, this vaccine could serve as a prophylactic and therapeutic intervention. Given the increasing incidence of COVID-19 cases due to the Omicron variant, RBD from the Omicron strain could serve as a candidate immunogen that can induce higher neutralization activities against the SARS-CoV-2 Omicron sublineages.
DOI: 10.6084/m9.figshare.24323094.v1
title: Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine

description: The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses a challenge to determine the optimal updated composition of the coronavirus disease 2019 (COVID-19) vaccine. The present study aimed to investigate the immunogenicity of the Delta monovalent vaccine, the Omicron monovalent vaccine, and the Delta and Omicron BA.1 bivalent vaccine. Three COVID-19 vaccines were designed using the heterologous DNA prime-protein boost strategy, with each vaccine containing either Delta receptor-binding domain (RBD) of the spike protein, Omicron RBD, or both Delta and Omicron antigens. Temporal serum antibody binding titers and neutralizing antibody titers induced by the three vaccines in New Zealand White rabbits were analyzed. To further dissect the vaccine elicited antibodies (mAb) responses at the molecular level, a panel of rabbit monoclonal antibodies (RmAbs) was generated by a high-throughput single B cell sorting and discovery pipeline and further comprehensively characterized. The Omicron monovalent vaccine induced higher antibody binding titers and neutralization activities than the Delta and Omicron bivalent vaccine. Four RmAbs with robust neutralization capacity were isolated from rabbits immunized with the Omicron or Delta monovalent vaccine. Notably, 9E11 isolated from the Omicron monovalent vaccine group neutralized all the Omicron subvariants with an IC<sub>50</sub> value ranging from 1.5 to 503.6 ng/mL; thus, this vaccine could serve as a prophylactic and therapeutic intervention. Given the increasing incidence of COVID-19 cases due to the Omicron variant, RBD from the Omicron strain could serve as a candidate immunogen that can induce higher neutralization activities against the SARS-CoV-2 Omicron sublineages.
DOI: 10.6084/m9.figshare.23654610
title: Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19

description: This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and NCT04566770). Both trials had low-dose and high-dose groups. Propensity score matching was used to adjust the baseline between one- and two-dose regimens. To predict the decrease in antibody titers 1 y after vaccination, half-lives of RBD-binding antibodies and pseudovirus neutralizing antibodies were computed. We obtained 34 and 29 pairs of participants in the low- and high-dose groups based on the propensity score matching. The two-dose regimen of Ad5-nCoV increased the peaking level of neutralizing antibodies compared to the one-dose regimen at day 28, but the responses of the neutralizing antibodies were not consistent with those of the RBD antibodies. Half-lives of the RBD-binding antibodies in the two-dose Ad5-nCoV regimen (202–209 days) were longer than those in the one-dose regimen (136–137 d); half-lives of the pseudovirus neutralizing antibody in the one-dose Ad5-nCoV regimen (177 d) were longer than those in the two-dose regimen (116–131 d). The predicted positive rates of RBD-binding antibodies in the one-dose regimen (34.1%–38.3%) would be lower than those in the two-dose Ad5-nCoV regimen (67.0%–84.0%), while the positive rates of pseudovirus neutralizing antibodies in the one-dose regimen (65.4%–66.7%) would be higher than those in the two-dose regimen (48.3%–58.0%). The two-dose Ad5-nCoV regimen with a 56-d interval had no effect on the persistence of neutralizing antibodies but slowed decay trend of RBD-binding antibodies.
DOI: 10.6084/m9.figshare.23654610.v1
title: Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19

description: This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and NCT04566770). Both trials had low-dose and high-dose groups. Propensity score matching was used to adjust the baseline between one- and two-dose regimens. To predict the decrease in antibody titers 1 y after vaccination, half-lives of RBD-binding antibodies and pseudovirus neutralizing antibodies were computed. We obtained 34 and 29 pairs of participants in the low- and high-dose groups based on the propensity score matching. The two-dose regimen of Ad5-nCoV increased the peaking level of neutralizing antibodies compared to the one-dose regimen at day 28, but the responses of the neutralizing antibodies were not consistent with those of the RBD antibodies. Half-lives of the RBD-binding antibodies in the two-dose Ad5-nCoV regimen (202–209 days) were longer than those in the one-dose regimen (136–137 d); half-lives of the pseudovirus neutralizing antibody in the one-dose Ad5-nCoV regimen (177 d) were longer than those in the two-dose regimen (116–131 d). The predicted positive rates of RBD-binding antibodies in the one-dose regimen (34.1%–38.3%) would be lower than those in the two-dose Ad5-nCoV regimen (67.0%–84.0%), while the positive rates of pseudovirus neutralizing antibodies in the one-dose regimen (65.4%–66.7%) would be higher than those in the two-dose regimen (48.3%–58.0%). The two-dose Ad5-nCoV regimen with a 56-d interval had no effect on the persistence of neutralizing antibodies but slowed decay trend of RBD-binding antibodies.
DOI: 10.6084/m9.figshare.24099596
title: Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer

description: The occurrence of markedly accelerated tumor growth during immunotherapy is considered a new mode of progression called hyperprogressive disease (HPD) and its impact on pancreatic cancer (PC) patients receiving immunotherapy is unknown. In this study, we described and explored the incidence, prognosis and predictors of HPD in patients with advanced PC treated with programmed cell death-1 (PD-1) inhibitors. We retrospectively analyzed clinicopathological data from 104 patients with advanced pancreatic cancer who were treated with PD-1 inhibitors at our institution during 2015–2020 and identified 10 (9.6%) patients with HPD. Overall survival (OS) was significantly poorer in patients with HPD compared to patients with progressive disease (PD) (median OS: 5.6 vs. 3.6 months, <i>p</i> &lt; .01). Clinicopathological factors associated with the occurrence of HPD included smoking, metastatic sites &gt;2, liver metastasis, antibiotic therapy within 21 days before immunotherapy (Abx B21), hemoglobin (Hb) level &lt;110 g/L, and PD-1 inhibitor treatment line &gt;2. Subgroup analysis showed that high levels of CA19-9 at baseline were associated with the development of subsequent HPD (<i>p</i> = .024) and a worse prognosis (mOS:16.2 months vs. 6.1 months, <i>p</i> &lt; .01). Our study demonstrated that HPD may occur in PC patients treated with PD-1 inhibitors and is associated with several clinicopathological characteristics and poor prognosis. The baseline tumor marker CA19-9 may be one of the early predictors of HPD development in PC patients receiving immunotherapy.